Combination Drug Therapy for the Management of Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Even though the number of AD patients is rapidly growing, there is no effective treatment for this neurodegenerative disorder. At present, implementation of effective treatment approaches for AD is vital to meet clinical needs. In AD research, priorities concern the development of disease-modifying therapeutic agents to be used in the early phases of AD and the optimization of the symptomatic treatments predominantly dedicated to the more advanced AD stages. Until now, available therapeutic agents for AD treatment only provide symptomatic treatment. Since AD pathogenesis is multifactorial, use of a multimodal therapeutic intervention addressing several molecular targets of AD-related pathological processes seems to be the most practical approach to modify the course of AD progression. It has been demonstrated through numerous studies, that the clinical efficacy of combination therapy (CT) is higher than that of monotherapy. In case of AD, CT is more effective, mostly when started early, at slowing the rate of cognitive impairment. In this review, we have covered the major studies regarding CT to combat AD pathogenesis. Moreover, we have also highlighted the safety, tolerability, and efficacy of CT in the treatment of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, the combination use of appropriate cholinesterase inhibitors, such as donepezil (4) and galantamine (6), or the combination of cholinesterase inhibitors with other neurologic drugs, metal chelators, or antioxidants, may yield surprising effects in the management of cholinergic drugs in AD, including efficacy, tolerability, and safety.402,408”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [402]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Lipton, S. A., Choi, Y.-B., Pan, Z.-H., Lei, S. Z., Chen, H.-S. V., Sucher, N. J., Loscalzo, J., Singel, D. J., & Stamler, J. S. (1993) · Nature · doi:10.1038/364626a0 · Cited by 2,433
Nichols, E., Szoeke, C. E. I., Vollset, S. E., Abbasi, N., Abd-Allah, F., Abdela, J., Aichour, M. T. E., Akinyemi, R. O., Alahdab, F., Asgedom, S. W., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30403-4 · Cited by 2,412
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Holmes, C., Boche, D., Wilkinson, D., Yadegarfar, G., Hopkins, V., Bayer, A., Jones, R. W., Bullock, R., Love, S., Neal, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61075-2 · Cited by 1,416
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113
Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond
Lipton, S. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1958 · Cited by 909
Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial
Quinn, J. F., Raman, R., Thomas, R. G., Yurko-Mauro, K., Nelson, E. B., Van Dyck, C., Galvin, J. E., Emond, J., Jack, C. R., Weiner, M., et al. (2010) · JAMA · doi:10.1001/jama.2010.1510 · Cited by 764
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Freund-Levi, Y., Eriksdotter-Jönhagen, M., Cederholm, T., Basun, H., Faxén-Irving, G., Garlind, A., Vedin, I., Vessby, B., Wahlund, L.-O., & Palmblad, J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1402 · Cited by 751
Lannfelt, L., Blennow, K., Zetterberg, H., Batsman, S., Ames, D., Harrison, J., Masters, C. L., Targum, S., Bush, A. I., Murdoch, R., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70167-4 · Cited by 725
Rinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Curtain, C. C., Ali, F., Volitakis, I., Cherny, R. A., Norton, R. S., Beyreuther, K., Barrow, C. J., Masters, C. L., Bush, A. I., & Barnham, K. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100175200 · Cited by 649
Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss
Talantova, M., Sanz-Blasco, S., Zhang, X., Xia, P., Akhtar, M. W., Okamoto, S.-I., Dziewczapolski, G., Nakamura, T., Cao, G., Pratt, A. E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306832110 · Cited by 600
Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options
Cummings, J. L., Tong, G., & Ballard, C. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180766 · Cited by 588
Bateman, R. J., Aisen, P. S., De Strooper, B., Fox, N. C., Lemere, C. A., Ringman, J. M., Salloway, S., Sperling, R. A., Windisch, M., & Xiong, C. (2010) · Alzheimer's Research & Therapy · doi:10.1186/alzrt59 · Cited by 573
Aisen, P. S. (2008) · JAMA · doi:10.1001/jama.300.15.1774 · Cited by 557
Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., et al. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70015-7 · Cited by 512
Metal Toxicity Links to Alzheimer's Disease and Neuroinflammation
Huat, T. J., Camats-Perna, J., Newcombe, E. A., Valmas, N., Kitazawa, M., & Medeiros, R. (2019) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.01.018 · Cited by 470
Drug development in Alzheimer’s disease: the path to 2025
Cummings, J., Aisen, P. S., DuBois, B., Frölich, L., Jack, C. R., Jones, R. W., Morris, J. C., Raskin, J., Dowsett, S. A., & Scheltens, P. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0207-9 · Cited by 459
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe
Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D. A., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d6476a · Cited by 438
PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses
Faux, N. G., Ritchie, C. W., Gunn, A., Rembach, A., Tsatsanis, A., Bedo, J., Harrison, J., Lannfelt, L., Blennow, K., Zetterberg, H., et al. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1390 · Cited by 405
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
Suh, S. W., Jensen, K. B., Jensen, M. S., Silva, D. S., Kesslak, P. J., Danscher, G., & Frederickson, C. J. (2000) · Brain Research · doi:10.1016/s0006-8993(99)02096-x · Cited by 350
A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease
Sano, M., Bell, K. L., Galasko, D., Galvin, J. E., Thomas, R. G., van Dyck, C. H., & Aisen, P. S. (2011) · Neurology · doi:10.1212/wnl.0b013e318228bf11 · Cited by 336
Neurotrophic factors in Alzheimer’s disease: role of axonal transport
Schindowski, K., Belarbi, K., & Buée, L. (2008) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2007.00378.x · Cited by 335
Fleisher, A. S., Raman, R., Siemers, E. R., Becerra, L., Clark, C. M., Dean, R. A., Farlow, M. R., Galvin, J. E., Peskind, E. R., Quinn, J. F., et al. (2008) · Archives of Neurology · doi:10.1001/archneur.65.8.1031 · Cited by 332
Parsons, C. G., Danysz, W., Dekundy, A., & Pulte, I. (2013) · Neurotoxicity Research · doi:10.1007/s12640-013-9398-z · Cited by 331
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease
Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthe, C., Lent, R. W., Younkin, S., Younkin, L., Schiff, R., & Weksler, M. E. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305
Aisen, P. S., Gauthier, S., Ferris, S. H., Saumier, D., Haine, D., Garceau, D., Duong, A., Suhy, J., Oh, J., Lau, W. C., et al. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.20612 · Cited by 295
Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., & Laughlin, M. A. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70090-5 · Cited by 290
Serum TNF-alpha levels are increased and correlate negatively with free IGF-I in Alzheimer disease
Álvarez, A., Cacabelos, R., Sanpedro, C., García-Fantini, M., & Aleixandre, M. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.02.012 · Cited by 278
Porsteinsson, A., Grossberg, G., Mintzer, J., & Olin, J. (2008) · Current Alzheimer Research · doi:10.2174/156720508783884576 · Cited by 272
Fernández-Bachiller, M. I., Pérez, C., González-Muñoz, G. C., Conde, S., López, M. G., Villarroya, M., García, A. G., & Rodríguez-Franco, M. I. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100329q · Cited by 268
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266
A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258
Vellas, B., Black, R., Thal, L., Fox, N., Daniels, M., McLennan, G., Tompkins, C., Leibman, C., Pomfret, M., & Grundman, M. (2009) · Current Alzheimer Research · doi:10.2174/156720509787602852 · Cited by 255
Wilcock, G. K., Ballard, C. G., Cooper, J. A., & Loft, H. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0302 · Cited by 253
A molecular approach in drug development for Alzheimer’s disease
Agatonovic-Kustrin, S., Kettle, C., & Morton, D. W. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.06.147 · Cited by 233
Long-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230
Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment
Cummings, J. L., Schneider, E., Tariot, P. N., & Graham, S. M. (2006) · Neurology · doi:10.1212/01.wnl.0000223333.42368.f1 · Cited by 223
Chronic Divalproex Sodium to Attenuate Agitation and Clinical Progression of Alzheimer Disease
Tariot, P. N. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.72 · Cited by 223
Gauthier, S., Loft, H., & Cummings, J. (2008) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1949 · Cited by 220
Zheng, H., Gal, S., Weiner, L. M., Bar‐Am, O., Warshawsky, A., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03340.x · Cited by 214
Uddin, M. S., Kabir, M. T., Al Mamun, A., Abdel-Daim, M. M., Barreto, G. E., & Ashraf, G. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1237-z · Cited by 212
Self-citationNoradrenergic dysfunction in Alzheimer's disease
Gannon, M., Che, P., Chen, Y., Jiao, K., Roberson, E. D., & Wang, Q. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00220 · Cited by 209
Harrington, C., Sawchak, S., Chiang, C., Davies, J., Donovan, C., M. Saunders, A., Irizarry, M., Jeter, B., Zvartau-Hind, M., H. van Dyck, C., et al. (2011) · Current Alzheimer Research · doi:10.2174/156720511796391935 · Cited by 197
Dodel, R., Rominger, A., Bartenstein, P., Barkhof, F., Blennow, K., Förster, S., Winter, Y., Bach, J.-P., Popp, J., Alferink, J., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70014-0 · Cited by 187
Gal, S., Zheng, H., Fridkin, M., & Youdim, M. B. H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03341.x · Cited by 185
Takada-Takatori, Y., Kume, T., Sugimoto, M., Katsuki, H., Sugimoto, H., & Akaike, A. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.04.007 · Cited by 185
Rosini, M., Simoni, E., Bartolini, M., Cavalli, A., Ceccarini, L., Pascu, N., McClymont, D. W., Tarozzi, A., Bolognesi, M. L., Minarini, A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800577j · Cited by 185
Combination Therapy in Alzheimer???s Disease: A Review of Current Evidence
Schmitt, B., Bernhardt, T., Moeller, H.-J., Heuser, I., & Fr??lich, L. (2004) · CNS Drugs · doi:10.2165/00023210-200418130-00001 · Cited by 182
Rountree, S. D., Chan, W., Pavlik, V. N., Darby, E. J., Siddiqui, S., & Doody, R. S. (2009) · Alzheimers Res Ther · doi:10.1186/alzrt7 · Cited by 181
Chronic divalproex sodium use and brain atrophy in Alzheimer disease
Fleisher, A. S., Truran, D., Mai, J. T., Langbaum, J. B. S., Aisen, P. S., Cummings, J. L., Jack, C. R., Weiner, M. W., Thomas, R. G., Schneider, L. S., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e318230a16c · Cited by 177
Circadian and sleep dysfunction in Alzheimer’s disease
Uddin, M. S., Tewari, D., Mamun, A. A., Kabir, M. T., Niaz, K., Wahed, M. I. I., Barreto, G. E., & Ashraf, G. M. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101046 · Cited by 173
Self-citationPasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., & Maria Rossini, P. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03325217 · Cited by 172
Savelieff, M. G., DeToma, A. S., Derrick, J. S., & Lim, M. H. (2014) · Accounts of Chemical Research · doi:10.1021/ar500152x · Cited by 172
Rasagiline: A novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity
Weinreb, O., Amit, T., Bar-Am, O., & Youdim, M. B. H. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.008 · Cited by 171
Henley, D. B., May, P. C., Dean, R. A., & Siemers, E. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903044982 · Cited by 168
Simoni, E., Daniele, S., Bottegoni, G., Pizzirani, D., Trincavelli, M. L., Goldoni, L., Tarozzo, G., Reggiani, A., Martini, C., Piomelli, D., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3009458 · Cited by 163
Serrano-Pozo, A., William, C. M., Ferrer, I., Uro-Coste, E., Delisle, M.-B., Maurage, C.-A., Hock, C., Nitsch, R. M., Masliah, E., Growdon, J. H., et al. (2010) · Brain · doi:10.1093/brain/awq056 · Cited by 159
Grossberg, G. T., Manes, F., Allegri, R. F., Gutiérrez-Robledo, L. M., Gloger, S., Xie, L., Jia, X. D., Pejović, V., Miller, M. L., Perhach, J. L., et al. (2013) · CNS Drugs · doi:10.1007/s40263-013-0077-7 · Cited by 158
Toxic tau: structural origins of tau aggregation in Alzheimer's disease
Uddin, M., Ashraf, G., Mamun, A., & Mathew, B. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.274329 · Cited by 156
Self-citationEmerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders
Uddin, M. S., Mamun, A. A., Jakaria, M., Thangapandiyan, S., Ahmad, J., Rahman, M. A., Mathew, B., Abdel-Daim, M. M., & Aleya, L. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2019.135624 · Cited by 154
Self-citationGrossberg, G., & Thomas, S. (2009) · Clinical Interventions in Aging · doi:10.2147/cia.s6666 · Cited by 151
Long-Term Efficacy and Safety of Celecoxib in Alzheimer’s Disease
Soininen, H., West, C., Robbins, J., & Niculescu, L. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000096588 · Cited by 143
Gauthier, S., Aisen, P. S., Ferris, S. H., Saumier, D., Duong, A., Haine, D., Garceau, D., Suhy, J., Oh, J., Lau, W., et al. (2009) · The Journal of nutrition, health and aging · doi:10.1007/s12603-009-0106-x · Cited by 135
EHT0202 in Alzheimers Disease: A 3-Month, Randomized, Placebo- Controlled, Double-Blind Study
Vellas, B., Sol, O., J. Snyder, P., Ousset, P.-J., Haddad, R., Maurin, M., Lemarie, J.-C., Desire, L., & P. Pando, M. (2011) · Current Alzheimer Research · doi:10.2174/156720511795256053 · Cited by 133
Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer’s Disease
Uddin, M. S., Kabir, M. T., Niaz, K., Jeandet, P., Clément, C., Mathew, B., Rauf, A., Rengasamy, K. R. R., Sobarzo-Sánchez, E., Ashraf, G. M., et al. (2020) · Molecules · doi:10.3390/molecules25061267 · Cited by 133
Self-citationTreatment Options in Alzheimer’s Disease: Maximizing Benefit, Managing Expectations
Farlow, M. R., Miller, M. L., & Pejovic, V. (2008) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000122962 · Cited by 129
Weinstock, M., Bejar, C., Wang, R.-H., Poltyrev, T., Gross, A., Finberg, J. P. M., & Youdim, M. B. H. (2000) · Springer eBooks · doi:10.1007/978-3-7091-6301-6_10 · Cited by 125
Deardorff, W. J., & Grossberg, G. (2016) · Drug Design, Development and Therapy · doi:10.2147/dddt.s86463 · Cited by 125
From Single Target to Multitarget/Network Therapeutics in Alzheimer’s Therapy
Zheng, H., Fridkin, M., & Youdim, M. (2014) · Pharmaceuticals · doi:10.3390/ph7020113 · Cited by 120
Uddin, M. S., & Kabir, M. T. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00197 · Cited by 119
Self-citationKabir, M. T., Uddin, M. S., Begum, M. M., Thangapandiyan, S., Rahman, M. S., Aleya, L., Mathew, B., Ahmed, M., Barreto, G. E., & Ashraf, G. M. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191008103141 · Cited by 116
Self-citationDeiana, S., Harrington, C. R., Wischik, C. M., & Riedel, G. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1394-2 · Cited by 115
Plastino, M., Fava, A., Pirritano, D., Cotronei, P., Sacco, N., Sperlì, T., Spano, A. L., Gallo, D., Mungari, P., Consoli, D., et al. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.09.022 · Cited by 115
Kabir, M. T., Sufian, M. A., Uddin, M. S., Begum, M. M., Akhter, S., Islam, A., Mathew, B., Islam, M. S., Amran, M. S., & Md. Ashraf, G. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191011102444 · Cited by 115
Self-citationNicotinic Receptors in Neurodegeneration
Posadas, I., Lopez-Hernandez, B., & Cena, V. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311030005 · Cited by 113
Bar‐Am, O., Yogev‐Falach, M., Amit, T., Sagi, Y., & Youdim, M. B. H. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02425.x · Cited by 109
Dantoine, T., Auriacombe, S., Sarazin, M., Becker, H., Pere, J.-J., & Bourdeix, I. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00769.x · Cited by 106
Cholinotrophic Molecular Substrates of Mild Cognitive Impairment in the Elderly
Mufson, E., Counts, S., Fahnestock, M., & Ginsberg, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507781788855 · Cited by 104
Combination Therapy for Alzheimerʼs Disease
Patel, L., & Grossberg, G. T. (2011) · Drugs & Aging · doi:10.2165/11591860-000000000-00000 · Cited by 103
Ihl, R., Frölich, L., Winblad, B., Schneider, L., Burns, A., Möller, H.-J., & WFSBP Task Force on Treatment Guidelines for Alzheimer's Disease and other Dementias (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2010.538083 · Cited by 97
Genetic Heterogeneity in Alzheimer Disease and Implications for Treatment Strategies
Dominantly Inherited Alzheimer Network, Ringman, J. M., Goate, A., Masters, C. L., Cairns, N. J., Danek, A., Graff-Radford, N., Ghetti, B., & Morris, J. C. (2014) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-014-0499-8 · Cited by 96
Growth hormone secretagogue MK-677: No clinical effect on AD progression in a randomized trial
Sevigny, J. J., Ryan, J. M., van Dyck, C. H., Peng, Y., Lines, C. R., & Nessly, M. L. (2008) · Neurology · doi:10.1212/01.wnl.0000335163.88054.e7 · Cited by 91
Prati, F., Bergamini, C., Fato, R., Soukup, O., Korabecny, J., Andrisano, V., Bartolini, M., & Bolognesi, M. L. (2016) · ChemMedChem · doi:10.1002/cmdc.201600014 · Cited by 90
Moore, A. H., Bigbee, M. J., Boynton, G. E., Wakeham, C. M., Rosenheim, H. M., Staral, C. J., Morrissey, J. L., & Hund, A. K. (2010) · Pharmaceuticals · doi:10.3390/ph3061812 · Cited by 86
Uddin, M. S., Kabir, M. T., Tewari, D., Mathew, B., & Aleya, L. (2020) · Science of The Total Environment · doi:10.1016/j.scitotenv.2019.134836 · Cited by 86
Self-citationCapurro, V., Busquet, P., Lopes, J. P., Bertorelli, R., Tarozzo, G., Bolognesi, M. L., Piomelli, D., Reggiani, A., & Cavalli, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056870 · Cited by 80
A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors
Jones, R. W. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2384 · Cited by 75
Feldman, H. H., Schmitt, F. A., & Olin, J. T. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213859.35355.59 · Cited by 71
Bar‐Am, O., Weinreb, O., Amit, T., & Youdim, M. B. H. (2008) · Journal of Molecular Neuroscience · doi:10.1007/s12031-008-9139-6 · Cited by 69
Peña-Altamira, E., Prati, F., Massenzio, F., Virgili, M., Contestabile, A., Bolognesi, M. L., & Monti, B. (2016) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2016.1121237 · Cited by 69
A review of the effects of memantine on clinical progression in Alzheimer's disease
Wilkinson, D. (2012) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2788 · Cited by 67
Choi, S. H., Park, K. W., Na, D. L., Han, H. J., Kim, E.-J., Shim, Y. S., Lee, J.-H., & The EXPECT Study Group (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.582484 · Cited by 67
Alvarez, X. A., Cacabelos, R., Sampedro, C., Couceiro, V., Aleixandre, M., Vargas, M., Linares, C., Granizo, E., García-Fantini, M., Baurecht, W., et al. (2011) · Current Alzheimer Research · doi:10.2174/156720511796391863 · Cited by 67
Mohs, R. C., Shiovitz, T. M., Tariot, P. N., Porsteinsson, A. P., Baker, K. D., & Feldman, P. D. (2009) · American Journal of Geriatric Psychiatry · doi:10.1097/jgp.0b013e3181aad585 · Cited by 65
Galantamine potentiates the neuroprotective effect of memantine against NMDA‐induced excitotoxicity
Lopes, J. P., Tarozzo, G., Reggiani, A., Piomelli, D., & Cavalli, A. (2013) · Brain and Behavior · doi:10.1002/brb3.118 · Cited by 64
Long-term progression of Alzheimer's disease in patients under antidementia drugs
Gillette‐Guyonnet, S., Andrieu, S., Nourhashemi, F., Gardette, V., Coley, N., Cantet, C., Gauthier, S., Ousset, P., Vellas, B., & REAL.FR study group (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.02.009 · Cited by 64
Schmitt, F. A., van Dyck, C. H., Wichems, C. H., & Olin, J. T. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213860.35355.d4 · Cited by 62
Farlow, M. R., Alva, G., Meng, X., & Olin, J. T. (2010) · Current Medical Research and Opinion · doi:10.1185/03007990903434914 · Cited by 60
Pathogenic Mechanisms of Heavy Metal Induced-Alzheimer’s Disease
Lee, H. J., Park, M. K., & Seo, Y. R. (2018) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-018-0340-x · Cited by 60
Grossberg, G. T., Pejović, V., Miller, M. L., & Graham, S. M. (2009) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000200013 · Cited by 59
Gannon, M., & Wang, Q. (2019) · Brain Research · doi:10.1016/j.brainres.2018.01.001 · Cited by 57
Emerging Potential of Naturally Occurring Autophagy Modulators Against Neurodegeneration
Rahman, M. A., Rahman, M. R., Zaman, T., Uddin, M. S., Islam, R., Abdel-Daim, M. M., & Rhim, H. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200107142541 · Cited by 57
Self-citationKlaver, A. C., Finke, J. M., Digambaranath, J. L., Balasubramaniam, M., & Loeffler, D. A. (2009) · International Immunopharmacology · doi:10.1016/j.intimp.2009.10.005 · Cited by 53
Uddin, M., Hossain, M., Mamun, A. A., Tewari, D., Asaduzzaman, M., Islam, M., & Abdel‐Daim, M. M. (2018) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/1995-7645.237189 · Cited by 53
Self-citationOxidative Stress in Alzheimer’s Disease: Molecular Hallmarks of Underlying Vulnerability
Uddin, M. S., & Kabir, M. T. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_5 · Cited by 52
Self-citationModeling an Anti-Amyloid Combination Therapy for Alzheimer’s Disease
Chow, V. W., Savonenko, A. V., Melnikova, T., Kim, H., Price, D. L., Li, T., & Wong, P. C. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000337 · Cited by 51
?7 Nicotinic Acetylcholine Receptor Mediated Neuroprotection in Parkinson's Disease
Kawamata, J., Suzuki, S., & Shimohama, S. (2012) · Current Drug Targets · doi:10.2174/138945012800399026 · Cited by 50
Uddin, M. S., Al Mamun, A., Asaduzzaman, M., Hosn, F., Abu Sufian, M., Takeda, S., Herrera-Calderon, O., Abdel-Daim, M. M., Uddin, G. M. S., Noor, M. A. A., et al. (2018) · Annals of Neurosciences · doi:10.1159/000481812 · Cited by 48
Self-citationUddin, M. S., Kabir, M. T., Rahman, M. M., Mathew, B., Shah, M. A., & Ashraf, G. M. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13244 · Cited by 44
Self-citationKupershmidt, L., Amit, T., Bar‐Am, O., Weinreb, O., & Youdim, M. B. H. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8304-7 · Cited by 42
Neuroprotection by the multitarget iron chelator M30 on age-related alterations in mice
Kupershmidt, L., Amit, T., Bar‐Am, O., Youdim, M. B. H., & Weinreb, O. (2012) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2012.03.001 · Cited by 40
Weiner, M. W., Sadowsky, C., Saxton, J. A., Hofbauer, R. K., Graham, S. M., Yu, S. Y., Li, S., Hsu, H., Suhy, J., Fridman, M., et al. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.09.003 · Cited by 40
Begum, M. M., Islam, A., Begum, R., Uddin, M. S., Rahman, M. S., Alam, S., Akter, W., Das, M., Rahman, M. S., & Imon, A. H. M. R. (2019) · Evidence-Based Complementary and Alternative Medicine · doi:10.1155/2019/1562038 · Cited by 40
Self-citationVaccination against Alzheimer disease: An update on future strategies
Fettelschoss, A., Zabel, F., & Bachmann, M. F. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28183 · Cited by 38
No additional benefit of HRT on response to rivastigmine in menopausal women with AD
Rigaud, A. S., André, G., Vellas, B., Touchon, J., & Pere, J. J. (2003) · Neurology · doi:10.1212/wnl.60.1.148-a · Cited by 38
Riepe, M. W., Adler, G., Ibach, B., Weinkauf, B., Tracik, F., & Gunay, I. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000100875 · Cited by 34
Zhong, K. L., Chen, F., Hong, H., Ke, X., Lv, Y., Tang, S. S., & Zhu, Y. (2018) · Metabolic Brain Disease · doi:10.1007/s11011-018-0227-1 · Cited by 33
Martel, J.-C., Assié, M. B., Bardin, L., Depoortère, R., Cussac, D., & Newman‐Tancredi, A. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00249.x · Cited by 28
KDS2010: A Potent Highly Selective and Reversible MAO-B Inhibitor for Alzheimer’s Disease
Mamun, A. A., & Uddin, M. S. (2020) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207323666200117103144 · Cited by 27
Self-citationCummings, J. L. (2007) · PubMed · Cited by 23
Rahman, A., Haque, A., Uddin, M. S., Mian, M. M., Sufian, M. A., Rahman, M. M., Ali, Y. M., Rafe, M. R., Abdel‐Daim, M. M., Uddin, M. J., et al. (2017) · Journal of Intellectual Disability - Diagnosis and Treatment · doi:10.6000/2292-2598.2017.05.02.3 · Cited by 20
Self-citationUddin, M. S., Uddin, G. M. S., Begum, M. M., Begum, Y., Herrera-Calderón, O., Islam, M. M., & Abdel‐Daim, M. M. (2017) · Journal of Pharmacy and Nutrition Sciences · doi:10.6000/1927-5951.2017.07.03.10 · Cited by 20
Self-citationHossain, M. S., Uddin, M. S., Kabir, M. T., Begum, M. M., Koushal, P., Herrera-Calderón, O., Akter, R., Asaduzzaman, M., & Abdel‐Daim, M. M. (2017) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/1229 · Cited by 15
Self-citationGrossberg, G. T., Manes, F. F., Allegri, R., Gutiérrez‐Robledo, L. M., Gloger, S., Xie, L., Jia, X. D., Perhach, J. L., & Graham, S. M. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.2476 · Cited by 10
Combination Drug Therapy for the Treatment of Alzheimer’s Disease
Alvarez, X. A., Linares, C., & Masliah, E. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.92 · Cited by 9
Hossain, M. S., Uddin, M., Kabir, M. A., Akhter, S., Goswami, S., Mamun, A. A., Herrera-Calderón, O., & Abdel‐Daim, M. M. (2017) · Annual Research & Review in Biology · doi:10.9734/arrb/2017/35692 · Cited by 9
Self-citationUddin, M. S., Hossain, M. S., Kabir, M. T., Rahman, I., Tewari, D., Jamiruddin, M. R., & Mamun, A. A. (2018) · Journal of Pharmacy and Nutrition Sciences · doi:10.6000/1927-5951.2018.08.03.6 · Cited by 8
Self-citationAisen, P. S., Schafer, K. A., Grundman, M., Pfeiffer, E., Sano, M., Davis, K. L., Farlow, M. R., Jin, S., Thomas, R. G., Thal, L. J., et al. (2003) · JAMA · doi:10.1001/jama.289.21.2819 · Cited by 5
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Multifunctional nanoparticle-mediated combining therapy for human diseases
Li, X., Peng, X., Zoulikha, M., Boafo, G. F., Magar, K. T., Ju, Y., & He, W. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01668-1 · Cited by 521
“442 Levodopa was launched in 1970 to treat PD motor symptoms, and fi ve years later, the fi rst combined product of levodopa and carbidopa was approved 443 .”
BackgroundER stress and UPR in Alzheimer’s disease: mechanisms, pathogenesis, treatments
Ajoolabady, A., Lindholm, D., Ren, J., & Pratico, D. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05153-5 · Cited by 261
“Pathologically, AD displays the intracellular accumulation of phosphorylated tau protein and extracellular aggregation of amyloid β (Aβ) peptides in the brain, leading to a progressive albeit gradual impairment in cognitive function, ultimately, clinical dementia [16, 20].”
BackgroundKabir, M. T., Rahman, M. H., Shah, M., Jamiruddin, M. R., Basak, D., Al-Harrasi, A., Bhatia, S., Ashraf, G. M., Najda, A., El-kott, A. F., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112610 · Cited by 181
Self-citationMolecular Mechanisms of ER Stress and UPR in the Pathogenesis of Alzheimer’s Disease
Uddin, M. S., Tewari, D., Sharma, G., Kabir, M. T., Barreto, G. E., Bin-Jumah, M. N., Perveen, A., Abdel-Daim, M. M., & Ashraf, G. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01929-y · Cited by 164
Self-citation
Metadata
- Authors
- Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M.
- Affiliations
- BRAC University (BD)
- Southeast University (BD)
- Centre National de la Recherche Scientifique (FR)
- King Abdulaziz University (SA)
- Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad 678557, India
- Princess Nourah bint Abdulrahman University (SA)
- Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
- Corresponding author
- Uddin, Md. Sahab
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-05-05
- Volume
- 21
- Issue
- 9
- Pages
- 3272
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7246721
- OpenAlex
- W3022707404
- Cited by
- 217
- References
- 135
- Citations by year
- 2026: 26 · 2025: 43 · 2024: 34 · 2023: 30 · 2022: 40 · 2021: 27 · 2020: 17
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by)
- HAL (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Griffith Research Online (submittedVersion, cc-by)
- Funders
- Princess Nourah Bint Abdulrahman University
- Deanship of Scientific Research, Princess Nourah Bint Abdulrahman University
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, combination therapy, multimodal therapy, disease-modifying therapy, symptomatic treatment, early intervention, cognitive impairment, drug safety and tolerability, drug efficacy
- MeSH terms
- Alzheimer Disease, Animals, Cholinesterase Inhibitors, Clinical Trials as Topic, Disease Susceptibility, Drug Therapy, Combination, Galantamine, Humans, Memantine, Dopamine Agents, Biomarkers, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.